CNS Pharmaceuticals (CNSP) Net Equity Issued and Repurchased (2019 - 2025)

CNS Pharmaceuticals (CNSP) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $501745.0 in Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 89.97% year-over-year to $501745.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.9 million (down 23.34% YoY) and the FY2025 annual result came in at $14.0 million, down 39.91% from the prior year.
• Net Equity Issued and Repurchased declined to $501745.0 in Q4 2025, from $5.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $12.4 million in Q3 2024 to a low of $132851.0 in Q3 2023.
• A 5-year average of $3.6 million and a median of $2.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 96.02% — and 2024, when it surged 9244.01%.
• Tracing CNSP's Net Equity Issued and Repurchased over 5 years: stood at $3.6 million in 2021, then surged by 51.64% to $5.4 million in 2022, then sank by 96.02% to $215641.0 in 2023, then surged by 2220.75% to $5.0 million in 2024, then slumped by 89.97% to $501745.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $501745.0 (Q4 2025), $5.0 million (Q4 2024), and $12.4 million (Q3 2024), per Business Quant data.